Purpose: Choroidal osteoma is a rare tumor which features intraocular bone formation. This tumor can be complicated by choroidal neovascularization which is a cause of impaired vision in this condition. We present a case of choroidal osteoma with choroidal neovascularization as a complication.

Methods: Case report with clinical and angiographic correlation.

Results: A 16 year old female presented with a choroidal osteoma in the left eye complicated by choroidal neovascularization. The patient was treated with Bevacizumab; an intravitreal anti-Vascular Endothelial Growth Factor (Anti-VEGF). Following treatment there was improvement in vision as well as resolution of the choroidal neovascular membrane.

Conclusion: We present a case of choroidal osteoma with choroidal neovascular membranes. Subfoveal Choroidal Neovascularization (CNV) associated with choroidal osteoma may be safely treated with bevacizumab. Larger studies are required to fully evaluate the management and long-term outcomes of anti-VEGF therapy for CNV associated with choroidal osteoma.

Infliximab is a chimeric monoclonal antibody against Tumor Necrosis Factor-α (TNF-α), initially developed for treatment of rheumatoid arthritis and inflammatory bowel disease

Purpose: To evaluate etiologies, management, and outcomes of patients with Giant Retinal Tears (GRT) undergoing primary surgery at tertiary referral center.

Methods: A Retrospective, consecutive case series of 94 patients with at least 3 months follow up after silicon oil removal. 57 eyes (60.6%) underwent vitrectomy, 36 eyes (38.3%) underwent combined vitrectomy with buckling and 1 eye (1.1%) underwent scleral buckling. Perfluorocarbon (PFCL) heavy liquid to flatten GRT f lap intraoperative has been used then PFCL air exchange then air silicon exchange in all eyes undergoing vitrectomy. Fellow eye was observed for retinal detachment.

Results: Idiopathic cause constitute 47 eyes (50%), 25 eyes (26.6%) are myopic and 22 eyes (23.4%) have history of trauma. 85 eyes (90.4%) achieved anatomic success. Visual acuity at the last follow-up was at least 20/400 in 71 eyes (75.5%) of patients. Recurrent retinal detachment after Silicon Oil Removal (SOR) was found in 21 eyes (22.3%) of which, 50% had Proliferative Vitreoretinopathy Grade C (PVR-C) or more (p value 0.03) and 20% had GRT size more than 180° (p value 0.04). Pars Plana Vitrectomy (PPV) alone (p value 0.89) or combined PPV with buckling (p value 0.98) have no significant correlation with recurrent Retinal Detachment (RD). 21% of the fellow eye had retinal detachment.

Conclusion: Idiopathic cause constitutes the majority 50%. Patients with GRT who underwent surgery achieved high anatomic success rate. PVR-C or more remain the most significant risk factor for recurrent RD after SOR whereas PPV alone or combined PPV with buckling have no significant correlation with recurrent RD.